
Replimune rose 113.4% from $9.01 to $19.23, ahead of the S&P 500's +9.7%. Its worst day was Apr 13 (−64.3%), and its low came Apr 13 at $1.70.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.77 beat the $-0.83 estimate on $0.00 revenue (est. $3.2M).
+5.8% · S&P 500 −0.8%
Replimune closed at its lowest level of the year, 81.1% below where the year started.
Story events cover the past 12 months · Times ET
−64.3%, the year's worst day, on 67M shares, the year's heaviest volume · S&P 500 +1.0%
Replimune shares rose 85.7%, while the S&P 500 rose 0.2%.
+85.7% · S&P 500 +0.2%
EPS of $-0.76 missed the $-0.70 estimate on $0.00 revenue (est. $5.6M).
−3.7% · S&P 500 +1.6%
Replimune shares rose 107.0%, while the S&P 500 rose 0.7%.
+107.0%, the year's best day · S&P 500 +0.7%
EPS of $-0.72 beat the $-0.76 estimate on $0.00 revenue (est. $7.5M).
−1.4% · S&P 500 −0.2%
EPS of $-0.54 beat the $-0.77 estimate on $0.00 revenue (est. $1.2M).
+23.1% · S&P 500 +0.3%
Replimune closed at its highest level of the year, 158.4% above where the year started.
+4.6% · S&P 500 −0.4%
Where it ended: a close of $19.23 on Nov 19, 2026. Up next: Q3 2027 earnings on Feb 2, 2027 (EPS est. $-0.49, revenue est. $8.3M).
Nothing in the past 12 months.
All REPL dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for REPL and SPY from Benzinga historical bars. Not investment advice.